{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T05:06:18Z","timestamp":1775106378030,"version":"3.50.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s13555-026-01701-5","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T13:23:35Z","timestamp":1773062615000},"page":"2117-2131","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Treatment Patterns and Health-Related Quality of Life in Patients with Alopecia Areata Stratified by Disease Severity in the USA"],"prefix":"10.1007","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6084-5617","authenticated-orcid":false,"given":"Arash","family":"Mostaghimi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed M.","family":"Soliman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sven G.","family":"Richter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jenny","family":"Austin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexa","family":"Russnak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,9]]},"reference":[{"issue":"2","key":"1701_CR1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-053137","volume":"12","author":"YMF Andersen","year":"2022","unstructured":"Andersen YMF, Nymand L, DeLozier AM, Burge R, Edson-Heredia E, Egeberg A. Patient characteristics and disease burden of alopecia areata in the Danish Skin Cohort. BMJ Open. 2022;12(2):e053137.","journal-title":"BMJ Open"},{"key":"1701_CR2","unstructured":"NAAF. Alopecia areata\u2014National Alopecia Areata Foundation 2025 [cited 2025 May 2]. https:\/\/www.naaf.org\/alopecia-areata\/."},{"issue":"3","key":"1701_CR3","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1177\/12034754231168839","volume":"27","author":"C Sibbald","year":"2023","unstructured":"Sibbald C. Alopecia areata: an updated review for 2023. J Cutan Med Surg. 2023;27(3):241\u201359.","journal-title":"J Cutan Med Surg"},{"issue":"12","key":"1701_CR4","doi-asserted-by":"publisher","first-page":"5504","DOI":"10.1007\/s12325-022-02338-4","volume":"39","author":"M Fridman","year":"2022","unstructured":"Fridman M, Ray M, Gandhi K, Shy ME, Mostaghimi A. Treatment patterns and treatment satisfaction among adults with alopecia areata in the United States. Adv Ther. 2022;39(12):5504\u201313.","journal-title":"Adv Ther"},{"key":"1701_CR5","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v103.12445","volume":"103","author":"N Done","year":"2023","unstructured":"Done N, Bartolome L, Swallow E, Gao W, Carley C, Wang T, et\u00a0al. Real-world treatment patterns among patients with alopecia areata in the USA: a retrospective claims analysis. Acta Derm Venereol. 2023;103:adv12445.","journal-title":"Acta Derm Venereol"},{"issue":"11","key":"1701_CR6","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1001\/jamadermatol.2023.3109","volume":"159","author":"H Lee","year":"2023","unstructured":"Lee H, Huang KP, Mostaghimi A, Choudhry NK. Treatment patterns for alopecia areata in the US. JAMA Dermatol. 2023;159(11):1253\u20137.","journal-title":"JAMA Dermatol"},{"key":"1701_CR7","unstructured":"Eli Lily. Olumiant US Package Insert. 2018."},{"key":"1701_CR8","unstructured":"Pfizer. Ritlecitinib US Package Insert. 2023."},{"issue":"4","key":"1701_CR9","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1111\/ced.14507","volume":"46","author":"A Egeberg","year":"2021","unstructured":"Egeberg A, Anderson S, Edson-Heredia E, Burge R. Comorbidities of alopecia areata: a population-based cohort study. Clin Exp Dermatol. 2021;46(4):651\u20136.","journal-title":"Clin Exp Dermatol"},{"issue":"9","key":"1701_CR10","doi-asserted-by":"publisher","first-page":"4646","DOI":"10.1007\/s12325-021-01845-0","volume":"38","author":"M Senna","year":"2021","unstructured":"Senna M, Ko J, Tosti A, Edson-Heredia E, Fenske DC, Ellinwood AK, et\u00a0al. Alopecia areata treatment patterns, healthcare resource utilization, and comorbidities in the US population using insurance claims. Adv Ther. 2021;38(9):4646\u201358.","journal-title":"Adv Ther"},{"key":"1701_CR11","doi-asserted-by":"publisher","first-page":"4881","DOI":"10.2147\/JIR.S331579","volume":"14","author":"K Chanprapaph","year":"2021","unstructured":"Chanprapaph K, Mahasaksiri T, Kositkuljorn C, Leerunyakul K, Suchonwanit P. Prevalence and risk factors associated with the occurrence of autoimmune diseases in patients with alopecia areata. J Inflamm Res. 2021;14:4881\u201391.","journal-title":"J Inflamm Res"},{"key":"1701_CR12","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18926","author":"A Muntyanu","year":"2023","unstructured":"Muntyanu A, Gabrielli S, Donovan J, Gooderham M, Guenther L, Hanna S, et\u00a0al. The burden of alopecia areata: a scoping review focusing on quality of life, mental health and work productivity. J Eur Acad Dermatol Venereol. 2023. https:\/\/doi.org\/10.1111\/jdv.18926.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"1701_CR13","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1007\/s40257-023-00805-4","volume":"24","author":"S Ly","year":"2023","unstructured":"Ly S, Manjaly P, Kamal K, Shields A, Wafae B, Afzal N, et\u00a0al. Comorbid conditions associated with alopecia areata: a systematic review and meta-analysis. Am J Clin Dermatol. 2023;24(6):875\u201393.","journal-title":"Am J Clin Dermatol"},{"issue":"7","key":"1701_CR14","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1007\/s13555-023-00941-z","volume":"13","author":"N Mesinkovska","year":"2023","unstructured":"Mesinkovska N, Craiglow B, Ball SG, Morrow P, Smith SG, Pierce E, et\u00a0al. The invisible impact of a visible disease: psychosocial impact of alopecia areata. Dermatol Ther. 2023;13(7):1503\u201315.","journal-title":"Dermatol Ther"},{"issue":"1","key":"1701_CR15","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/bjd.21055","volume":"187","author":"AE Macbeth","year":"2022","unstructured":"Macbeth AE, Holmes S, Harries M, Chiu WS, Tziotzios C, de Lusignan S, et\u00a0al. The associated burden of mental health conditions in alopecia areata: a population-based study in UK primary care. Br J Dermatol. 2022;187(1):73\u201381.","journal-title":"Br J Dermatol"},{"issue":"5","key":"1701_CR16","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1159\/000497166","volume":"5","author":"RDC Velez-Muniz","year":"2019","unstructured":"Velez-Muniz RDC, Peralta-Pedrero ML, Jurado-Santa Cruz F, Morales-Sanchez MA. Psychological profile and quality of life of patients with alopecia areata. Skin Appendage Disord. 2019;5(5):293\u20138.","journal-title":"Skin Appendage Disord"},{"issue":"9","key":"1701_CR17","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1001\/jamadermatol.2024.2404","volume":"160","author":"A Mostaghimi","year":"2024","unstructured":"Mostaghimi A, Soliman AM, Li C, Barqawi YK, Grada A. Immune-mediated and psychiatric comorbidities among patients newly diagnosed with alopecia areata. JAMA Dermatol. 2024;160(9):945\u201352.","journal-title":"JAMA Dermatol"},{"issue":"6","key":"1701_CR18","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1111\/1346-8138.16360","volume":"49","author":"E Edson-Heredia","year":"2022","unstructured":"Edson-Heredia E, Aranishi T, Isaka Y, Anderson P, Marwaha S, Piercy J. Patient and physician perspectives on alopecia areata: a real-world assessment of severity and burden in Japan. J Dermatol. 2022;49(6):575\u201383.","journal-title":"J Dermatol"},{"issue":"4","key":"1701_CR19","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1007\/s13555-024-01133-z","volume":"14","author":"S Vano-Galvan","year":"2024","unstructured":"Vano-Galvan S, Egeberg A, Piraccini BM, Marwaha S, Reed C, Johansson E, et\u00a0al. Characteristics and management of patients with alopecia areata and selected comorbid conditions: results from a survey in five European countries. Dermatol Ther (Heidelb). 2024;14(4):1027\u201337.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"1","key":"1701_CR20","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s13555-022-00864-1","volume":"13","author":"K Gandhi","year":"2023","unstructured":"Gandhi K, Shy ME, Ray M, Fridman M, Vaghela S, Mostaghimi A. The association of alopecia areata-related emotional symptoms with work productivity and daily activity among patients with alopecia areata. Dermatol Ther (Heidelb). 2023;13(1):285\u201398.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"12","key":"1701_CR21","doi-asserted-by":"publisher","first-page":"3121","DOI":"10.1007\/s13555-023-01057-0","volume":"13","author":"S Vano-Galvan","year":"2023","unstructured":"Vano-Galvan S, Blume-Peytavi U, Farrant P, Reygagne P, Johansson E, Reed C, et\u00a0al. Physician- and patient-reported severity and quality of life impact of alopecia areata: results from a real-world survey in five European countries. Dermatol Ther. 2023;13(12):3121\u201335.","journal-title":"Dermatol Ther"},{"issue":"1","key":"1701_CR22","doi-asserted-by":"publisher","first-page":"S62","DOI":"10.1016\/j.jisp.2020.05.007","volume":"20","author":"N Mesinkovska","year":"2020","unstructured":"Mesinkovska N, King B, Mirmirani P, Ko J, Cassella J. Burden of illness in alopecia areata: a cross-sectional online survey study. J Invest Dermatol Symp Proc. 2020;20(1):S62\u20138.","journal-title":"J Invest Dermatol Symp Proc"},{"issue":"11","key":"1701_CR23","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1185\/03007990802457040","volume":"24","author":"P Anderson","year":"2008","unstructured":"Anderson P, Benford M, Harris N, Karavali M, Piercy J. Real-world physician and patient behaviour across countries: disease-specific programmes\u2014A means to understand. Curr Med Res Opin. 2008;24(11):3063\u201372.","journal-title":"Curr Med Res Opin"},{"issue":"12","key":"1701_CR24","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1080\/03007995.2023.2279679","volume":"39","author":"P Anderson","year":"2023","unstructured":"Anderson P, Higgins V, Courcy J, Doslikova K, Davis VA, Karavali M, et\u00a0al. Real-world evidence generation from patients, their caregivers and physicians supporting clinical, regulatory and guideline decisions: an update on Disease Specific Programmes. Curr Med Res Opin. 2023;39(12):1707\u201315.","journal-title":"Curr Med Res Opin"},{"key":"1701_CR25","unstructured":"Babineaux SM, Curtis B, Holbrook T, Milligan G, Piercy J. Evidence for validity of a national physician and patient-reported, cross-sectional survey in China and UK: the Disease Specific Programme (2044\u20136055 (Electronic))."},{"key":"1701_CR26","doi-asserted-by":"crossref","unstructured":"Higgins V, Piercy J, Roughley A, Milligan G, Leith A, Siddall J, et\u00a0al. Trends in medication use in patients with type 2 diabetes mellitus: a long-term view of real-world treatment between 2000 and 2015. 2016(1178\u20137007 (Print)).","DOI":"10.2147\/DMSO.S120101"},{"issue":"4","key":"1701_CR27","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1111\/bjd.18883","volume":"183","author":"KW Wyrwich","year":"2020","unstructured":"Wyrwich KW, Kitchen H, Knight S, Aldhouse NVJ, Macey J, Nunes FP, et\u00a0al. The Alopecia Areata Investigator Global Assessment scale: a measure for evaluating clinically meaningful success in clinical trials. Br J Dermatol. 2020;183(4):702\u20139.","journal-title":"Br J Dermatol"},{"issue":"2","key":"1701_CR28","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/S0022-3999(01)00296-3","volume":"52","author":"I Bjelland","year":"2002","unstructured":"Bjelland I, Dahl AA, Haug TT, Neckelmann D. The validity of the Hospital Anxiety and Depression Scale: an updated literature review. J Psychosom Res. 2002;52(2):69\u201377.","journal-title":"J Psychosom Res"},{"issue":"2","key":"1701_CR29","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1111\/bjop.12637","volume":"114","author":"M Lloyd","year":"2023","unstructured":"Lloyd M, Sugden N, Thomas M, McGrath A, Skilbeck C. The structure of the Hospital Anxiety and Depression Scale: theoretical and methodological considerations. Br J Psychol. 2023;114(2):457\u201375.","journal-title":"Br J Psychol"},{"issue":"1","key":"1701_CR30","doi-asserted-by":"publisher","first-page":"S41","DOI":"10.1016\/j.jisp.2017.10.009","volume":"19","author":"TR Mendoza","year":"2018","unstructured":"Mendoza TR, Osei J, Duvic M. The utility and validity of the Alopecia Areata Symptom Impact Scale in measuring disease-related symptoms and their effect on functioning. J Invest Dermatol Symp Proc. 2018;19(1):S41\u20136.","journal-title":"J Invest Dermatol Symp Proc"},{"issue":"1","key":"1701_CR31","doi-asserted-by":"publisher","first-page":"S51","DOI":"10.1038\/jidsymp.2013.19","volume":"16","author":"TR Mendoza","year":"2013","unstructured":"Mendoza TR, Osei JS, Shi Q, Duvic M. Development of the Alopecia Areata Symptom Impact Scale. J Investig Dermatol Symp Proc. 2013;16(1):S51\u20132.","journal-title":"J Investig Dermatol Symp Proc"},{"issue":"2","key":"1701_CR32","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1177\/120347540100500202","volume":"5","author":"M-M Chren","year":"2001","unstructured":"Chren M-M, Lasek RJ, Sahay AP, Sands LP. Measurement properties of Skindex-16: a brief quality-of-life measure for patients with skin diseases. J Cutan Med Surg. 2001;5(2):105\u201310.","journal-title":"J Cutan Med Surg"},{"key":"1701_CR33","unstructured":"EPHMRA. EPHMRA code of conduct 2024. 2024."},{"key":"1701_CR34","unstructured":"Pearl IRB. Pearl IRB submission guide and policies. 2014."},{"issue":"6","key":"1701_CR35","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1159\/000501940","volume":"5","author":"AK Gupta","year":"2019","unstructured":"Gupta AK, Carviel JL, Foley KA, Shear NH, Piraccini BM, Piguet V, et\u00a0al. Monotherapy for alopecia areata: a systematic review and network meta-analysis. Skin Appendage Disord. 2019;5(6):331\u20137.","journal-title":"Skin Appendage Disord"},{"issue":"1","key":"1701_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/1710-1492-9-30","volume":"9","author":"D Liu","year":"2013","unstructured":"Liu D, Ahmet A, Ward L, Krishnamoorthy P, Mandelcorn ED, Leigh R, et\u00a0al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin Immunol. 2013;9(1):30.","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"2","key":"1701_CR37","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.abd.2023.05.005","volume":"99","author":"LCP Tavares","year":"2024","unstructured":"Tavares LCP, Caetano LVN, Ianhez M. Side effects of chronic systemic glucocorticoid therapy: what dermatologists should know. An Bras Dermatol. 2024;99(2):259\u201368.","journal-title":"An Bras Dermatol"},{"issue":"4","key":"1701_CR38","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1007\/s13555-022-00702-4","volume":"12","author":"HL Gelhorn","year":"2022","unstructured":"Gelhorn HL, Cutts K, Edson-Heredia E, Wright P, Delozier A, Shapiro J, et\u00a0al. The relationship between patient-reported severity of hair loss and health-related quality of life and treatment patterns among patients with alopecia areata. Dermatol Ther. 2022;12(4):989\u201397.","journal-title":"Dermatol Ther"},{"issue":"2","key":"1701_CR39","doi-asserted-by":"publisher","DOI":"10.3390\/cosmetics11020055","volume":"11","author":"A Courtney","year":"2024","unstructured":"Courtney A, Su JC. Wigs and alopecia areata: psychosocial impact and economic considerations. Cosmet. 2024;11(2):55.","journal-title":"Cosmet"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01701-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01701-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01701-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T03:38:37Z","timestamp":1775101117000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-026-01701-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,9]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["1701"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01701-5","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,9]]},"assertion":[{"value":"29 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Arash Mostaghimi has received personal fees from Hims & Hers Health, Inc, AbbVie Inc, Sun Pharma, Pfizer, Digital Diagnostics, Lilly, Equillium, ASLAN Pharmaceuticals, Boehringer Ingelheim, Figure 1, Acom Healthcare, Olaplex, and Legacy Healthcare; and is an editorial board member of\n                      Dermatology and Therapy\n                      . Arash Mostaghimi was not involved in the selection of peer reviewers for the manuscript or any of the subsequent editorial decisions. Ahmed M. Soliman is an employee of AbbVie and may hold stock or stock options or patents in AbbVie. Sven G. Richter is an employee of AbbVie and may hold stock or stock options in AbbVie. Jenny Austin is an employee of Adelphi Real World. Alexa Russnak is an employee of Adelphi Real World.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Data collection was undertaken in line with European Pharmaceutical Marketing Research Association guidelines and as such did not require ethics committee approval. The study protocol was reviewed by the Pearl Institutional Review Board and deemed to be exempt (ID no. 2023-0401). Using a check box, patients provided informed consent for use of their anonymized and aggregated data for research and publication in scientific journals. No identifiable protected health information was collected; all data were aggregated and de-identified before receipt.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}